Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer pill makeover may mess with treatment adherence

NCT ID NCT07664683

Knowledge-focused Sponsor: Universidad Miguel Hernandez de Elche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape, or packaging cause confusion or missed doses, and to inform better policies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral antineoplastics (chemotherapy pills)
What this could lead to
If successful, this could lead to policies that keep pill appearance consistent, helping cancer patients stay on track with their treatment.
What could go wrong
This is an observational study, not testing a new drug. Results may not apply to all cancer types or settings, and adherence is hard to measure accurately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 334 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The 2023 data from the hospitals where the study will be carried out shows that 517 patients were treated with one of the ANEOs included in the study. Given the required sample size of 334 patients, 112 patients will be consecutively admitted to each hospital, including those who meet the eligibility criteria, and will be followed for six months. For the qualitative investigation of objective 2 and participation in the focus groups, cancer patients treated with ANEOs will be contacted via the Spanish Patient Forum (3 gruops, 8-12 participants each)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Objective 1: Inclusion criteria: ANEOs included in the pharmacotherapeutic guide of the three hospitals for two years of follow-up (June 2025-2027) will be included. Objectives 2-5: Inclusion criteria: * Patients on treatment for at least 6 months with one of the following ANEOs will be included: capecitabine (L01BC06) (not used as adjuvant in short cycles), imatinib (L01EA01), everolimus (L04AA18), abiraterone (L02BX03) and lenalidomide (L04AX04), at the time of a change in their usual treatment (from brand to generic or between two generics). * Patients on treatment with ANEOs who meet the established criteria and who change their treatment from brand to generic or from one generic to another generic during the study period may also be included. Exclusion criteria: * Individuals who collect medication for others and those who are institutionalised will be excluded. * Patients who have been admitted to hospital in the last 4 weeks are also excluded, due to the increased control of their medication. Objective 2( Qualitative analysis) \- Spanish Patient Forum

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, patient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence, patient Cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad Miguel Hernández

    RECRUITING

    San Juan, Alicante, 03550, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.